Dr. Rigotti is an internationally known expert in tobacco cessation and is the Primary Investigator of the ORCA-2 Phase 3 clinical trial of cytisinicline. She is a Professor of Medicine at Harvard Medical School and Past President of both the Society of General Internal Medicine and the Society for Research in Nicotine and Tobacco. Dr. Rigotti founded and directs the Tobacco Research and Treatment Center at Massachusetts General Hospital whose mission is to develop innovative and effective smoking cessation treatments delivered in health care settings.
Dr. Benowitz is Emeritus Professor of Medicine, Division of Cardiology at the University of California San Francisco. He was Chief of the Division of Clinical Pharmacology and Experimental Therapeutics at UCSF for 35 years. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 700 research papers and maintains an active clinical practice in cardiovascular medicine and medical toxicology. He has served as a member of the National Institutes of Health Pharmacology Study Section, the FDA Nonprescription Drug Advisory Committee, and the FDA Tobacco Products Science Advisory Committee. He is Past President of the American Society for Clinical Pharmacology and Therapeutics and Society for Research on Nicotine and Tobacco.
Dr. Nides is the President of LA Clinical Trials, LLC, specializing in clinical research and development of products and medications to help smokers quit using combustible tobacco. Dr. Nides has been the principal investigator of over 60 smoking cessation trials, including the ORCA-1 Phase 2b clinical trial of cytisinicline. Dr. Nides was a smoking cessation researcher in the Pulmonary and Critical Care Dept. of the UCLA School of Medicine and has trained thousands of physicians, pharmacists, nurses, and other health care professionals on ways to help smokers quit.
Dr. Prochaska is a Professor in the Department of Medicine at Stanford University, Deputy Director of the Stanford Prevention Research Center, and a member of the Stanford Cancer Institute. She is a licensed clinical psychologist with addiction medicine privileges at Stanford Healthcare. Her research program leverages technology to study tobacco and other addictive behaviors, spanning community-based epidemiologic studies, randomized controlled trials, and policy analysis. Dr. Prochaska is a Past President of the Society for Research on Nicotine and Tobacco (SRNT). She has published over 250 peer-reviewed articles and serves on the Editorial Boards of JAMA Internal Medicine and Health Psychology.
Dr. Leischowis a Professor of Population Health, Executive Director of Clinical and Translational Science at Arizona State University, and an investigator on the ORCA-2 Phase 3 clinical trial of cytisinicline. Dr. Leischow is a past president of the Society for Research on Nicotine and Tobacco (SRNT). He previously served as the Chief of Tobacco Control Research Branch at the National Cancer Institute and Senior Advisor for Tobacco Policy in the Office of the Secretary of the U.S. Department of Health and Human Services.